Eli Lilly and Company

Michael Alan Robertson

Michael Robert Wiley

Larry C Blaszczak

Kenneth Allen Savin

Qing Shi

Scott Martin Sheehan

Shon Roland Pulley

Albert Kudzovi Amegadzie

Louis Nickolaus Jungheim

Brian Morgan Watson

Erik James Hembre, Ii

Kevin Matthew Gardinier

Jian Eric Hong

Philip Arthur Hipskind

John Michael Morin, Jr

Brian Stephen Muehl

Theo Schotten

Michael Dean Kinnick

Nancy June Snyder

James Arthur Nixon

Brian Michael Mathes

David Michael Remick

Lawrence Joseph Heinz, Ii

James Ronald Gillig

Carsten Ott

Yen-Shi Lai

Jochen Ammenn

Lawrence John Slieker

Larry Chris Blaszczak

Erik James Hembre

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12; R9 is selected from H &#x2014;NR13C(O)R14 and &#x2014;C(O)NR10R11; R12 is selected from H, C-Calkyl and C-Ccycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Pyridine derivatives as dipeptedyl peptidase inhibitors

The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl, C-Chaloalkyl, hydroxy C-Calkyl, &#x2014;C(O)R9 and &#x2014;SOR9, or R7 and R8 combine to form (III), (IV); W is selected from CR1O and CR15, R1O is selected from H, halo, &#x2014;C(O)NR13R14, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl and hydroxy C-Calkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH, CF, aryl, heteroaryl, C-Calkylaryl or C-Calkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

1-amino linked compounds

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12, R9 is selected from H and &#x2014;C(O)NR1OR1 1, R12 is selected from H, C-Calkyl and C-Ccycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Phenyl compounds and their use in the treatment of Type II diabetes

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C-Calkane-diyl; Ris phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C-Calkyl, C-Calkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; Ris a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) 

Triazole derivatives as tachykinin receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins 

Tachykinin receptor antagonists

Growing community of inventors

Indianapolis, IN, United States of America

Michael Alan Robertson